secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0000950170-23-073016
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology amends loan agreement; extends draw period to June 30, 2024 and adds ASPEN-06 milestone
--------------------------------------------------------------------------------

- Term A Loan draw period extended from Dec 31, 2023 to June 30, 2024.
- Future Term A funding requires Phase 2 of ASPEN-06 in gastric cancer to be ongoing or have positive data.
- Contingency fee of $600,000 payable to lenders if prepaid outside refinancing with Oxford and SVB.
- Remaining undrawn Term A commitment reallocated to Term B and C after June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/alxo-20231222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-073016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer